This review discusses the expanding armamentarium of antiplatelet therapies for acute coronary syndrome and highlights future directions such as pharmacogenomics and point-of-care testing.
No takes yet. Share an insight, caveat, or question.
May support evolving antiplatelet choices in ACS; leaves open the role of pharmacogenomics and point-of-care testing.
Eric J. Topol (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: